Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial

Y.H. Park; K.H. Jung; J. Sohn; K.S. Lee; J.H. Kim; Y. Yang; E. Baek; H. Han; S-A. Im

doi:10.1016/j.annonc.2022.03.195

YUHSpace

BROWSE

0 119

Cited 0 times in

Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial

Authors: Y.H. Park ; K.H. Jung ; J. Sohn ; K.S. Lee ; J.H. Kim ; Y. Yang ; E. Baek ; H. Han ; S-A. Im

Citation: ANNALS OF ONCOLOGY, Vol.33(Supplement 3) : S207-S208, 2022-05

Journal Title: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Issue Date: 2022-05

Full Text: https://www.sciencedirect.com/science/article/pii/S0923753422005749

DOI: 10.1016/j.annonc.2022.03.195

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/194660

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial

YUHSpace

BROWSE

Browse

Links